AUS
NZ
UK
CA
USA
IND
Highlights
- FDA approval granted for feasibility study of SCD-ADULT in adult patients with acute heart failure.
- $3.6 million NIH grant secured to fund the study across five clinical sites.
- Breakthrough Device Designation awarded to SCD-ADULT by the FDA in September 2023.
SeaStar Medical (NASDAQ:ICU) has received approval from the U.S. Food and Drug Administration (FDA) for an investigational device exemption (IDE) to study their Selective Cytopheretic Device (SCD-ADULT) in reducing inflammation in adult patients suffering from acute heart failure and worsening renal function. This marks a significant milestone in the company's efforts to advance its innovative device in the treatment of cardiorenal syndrome.
The approved feasibility study will enroll 20 patients across up to five clinical sites and will be fully funded by a generous $3.6 million National Institutes of Health (NIH) grant awarded to Innovative BioTherapies. This research is crucial for determining the effectiveness of the SCD-ADULT device in managing inflammation, a key factor in the progression of cardiorenal syndrome.
The study will be led by Dr. H. David Humes, the inventor of the SCD device, and SeaStar Medical will serve as the clinical research organization (CRO) overseeing the study. The company’s expertise in conducting clinical research will ensure the study is executed with the highest standards of quality and precision.
In addition to the IDE approval, the SCD-ADULT device has already been granted Breakthrough Device Designation by the FDA's Center for Biologics Evaluation and Research (CBER) in September 2023, specifically for treating cardiorenal syndrome in patients with left ventricular assist devices (LVAD). This designation is designed to accelerate the development and review of innovative devices that address serious or life-threatening conditions, underscoring the potential of the SCD-ADULT device to make a significant impact in treating cardiorenal syndrome.
SeaStar Medical has identified the total addressable market for the SCD-ADULT device in cardiorenal syndrome at over $1 billion annually in the U.S. alone. This underscores the substantial commercial opportunity for the device, particularly as the prevalence of acute heart failure and renal dysfunction continues to rise, making innovative treatments like the SCD-ADULT increasingly necessary.
While the approval of the IDE is a major achievement, the study remains in its early stages. The feasibility study will include 20 patients, and the data gathered will inform the design of a larger pivotal study, which will be required for full regulatory approval. As such, this is a crucial phase in the clinical development of the SCD-ADULT device, with further testing and validation needed before the device can achieve widespread commercial availability.
Nevertheless, the progress made by SeaStar Medical in obtaining FDA approval, securing NIH funding, and receiving Breakthrough Device Designation reflects the company's potential to lead in the treatment of cardiorenal syndrome. Investors and stakeholders will be closely monitoring the feasibility study’s progress, as it could provide critical insights into the device’s future success in addressing a significant unmet medical need.
